Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
167.6 EUR | +0.15% | +0.66% | +16.34% |
May. 28 | MERCK KGAA : Jefferies reaffirms its Buy rating | ZD |
May. 27 | MERCK : A lower starting point for future growth |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The firm trades with high earnings multiples: 24.07 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.72 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.34% | 79.03B | A | ||
+8.65% | 8.78B | A- | ||
-16.33% | 4.83B | A- | ||
+51.22% | 4.65B | - | ||
+2.18% | 3.89B | B- | ||
+20.51% | 2.34B | B | ||
-26.79% | 2.18B | C- | ||
+15.12% | 2.11B | - | - | |
-36.56% | 2B | - | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA